Skip to main content
SpringerLink
Log in

Cardiac Complications

  • Chapter
Oncology

Abstract

Cardiac toxicity is a well-recognized serious side effect of chemotherapy. Since early reports of heart failure in children treated with doxorubicin,1 anthracyclines remain the best known chemotherapeutic agents clearly linked to cardiotoxicity. There are, however, a number of other chemotherapeutic agents that cause cardiotoxicity which are still not so well recognized in clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Tan C, Tasaka H, Kou-Ping Y, et al. Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease: clinical evaluation with special reference to childhood leukemia. Cancer (Phila) 1967;20:333–353.

    Article  PubMed  CAS  Google Scholar 

  2. Hitchcock-Bryan S, Jeal GRC. The impact of induction anthra-cyclines on long-term failure-free survival in childhood acute lymphoblastic leukemia. Med Pediatr Oncol 1986;14:211–215.

    Article  PubMed  CAS  Google Scholar 

  3. Ettinghausen SE, Bonow RO, Palmeri ST, et al. Prospective study of cardiomyopathy induced by adjuvant doxorubicin therapy in patients with soft-tissue sarcomas. Arch Surg 1986;121:1445–1451.

    PubMed  CAS  Google Scholar 

  4. Frishman WH, Sung HM, Yee HC, et al. Cardiovascular toxicity with cancer chemotherapy. Curr Probl Cancer 1997;21:301–360.

    Article  PubMed  CAS  Google Scholar 

  5. Ferrans VJ. Overview of cardiac pathology in relation to anthracycline cardiotoxicity. Cancer Treat Rep 1978;62:955–961.

    PubMed  CAS  Google Scholar 

  6. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 2000;22:263–302.

    Article  PubMed  CAS  Google Scholar 

  7. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710–717.

    Google Scholar 

  8. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med 1996;125:47–58.

    PubMed  CAS  Google Scholar 

  9. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991;266:1672–1677.

    Article  PubMed  CAS  Google Scholar 

  10. Boucek RJ, Miracle A, Anderson M, Engelman R, Atkinson J, Dodd DA. Persistent effects of doxorubicin on cardiac gene expression. J Mol Cell Cardiol 1999;31:1435–1446.

    Article  PubMed  CAS  Google Scholar 

  11. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991;324:808–815.

    Article  PubMed  CAS  Google Scholar 

  12. Bu’Lock FA, Mott MG, Oakhill A, Martin RP. Left ventricular diastolic filling patterns associated with progressive anthracycline-induced myocardial damage: a prospective study. Pediatr Cardiol 1999;20:252–263.

    Article  PubMed  CAS  Google Scholar 

  13. Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995;332:1738–1743.

    Article  PubMed  CAS  Google Scholar 

  14. Grenier MA, Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol 1998;25:72–85.

    PubMed  CAS  Google Scholar 

  15. Legha SS, Benjamin RS, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982;96:133–139.

    PubMed  CAS  Google Scholar 

  16. Torti FM, Bristow MR, Howes AE, et al. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med 1983;99:745–749.

    PubMed  CAS  Google Scholar 

  17. Weiss AJ, Metter GE, Fletcher WS, Wilson WL, Grage TB, Ramirez G. Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity. Cancer Treat Rep 1976;60:813–822.

    PubMed  CAS  Google Scholar 

  18. Weiss AJ, Manthel RW. Experience with the use of adriamycin in combination with other anticancer agents using a weekly schedule, with particular reference to lack of cardiac toxicity. Cancer (Phila) 1977;40:2046–2052.

    Article  PubMed  CAS  Google Scholar 

  19. Chlebowski RT, Paroly WS, Pugh RP, et al. Adriamycin given as a weekly schedule without a loading course: clinically effective with reduced incidence of cardiotoxicity. Cancer Treat Rep 1980;64:47–51.

    PubMed  CAS  Google Scholar 

  20. Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, Lipshultz SE. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol 1997;15:1544–1552.

    PubMed  CAS  Google Scholar 

  21. Silber JH, Jakacki RI, Larsen RL, Goldwein JW, Barber G. Increased risk of cardiac dysfunction after anthracyclines in girls. Med Pediatr Oncol 1993;21:477–479.

    Article  PubMed  CAS  Google Scholar 

  22. Bristow MR, Mason JW, Billingham ME, Daniels JR. Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann Intern Med 1978;88:168–175.

    PubMed  CAS  Google Scholar 

  23. Praga C, Beretta G, Vigo PL, et al. Adriamycin cardiotoxicity: a survey of 1,273 patients. Cancer Treat Rep 1979;63:827–834.

    PubMed  CAS  Google Scholar 

  24. Pihkala J, Saarinen UM, Lundstrom U, et al. Myocardial function in children and adolescents after therapy with anthracyclines and chest irradiation. Eur J Cancer 1996;32A:97–103.

    Article  PubMed  CAS  Google Scholar 

  25. Kremer LC, van Dalen EC, Offringa M, Ottenkamp J, Voute PA. Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol 2001;19:191–196.

    PubMed  CAS  Google Scholar 

  26. Friedman MA, Bozdech MJ, Billingham ME, Rider AK. Doxorubicin cardiotoxicity. Serial endomyocardial biopsies and systolic time intervals. JAMA 1978;240:1603–1606.

    Article  PubMed  CAS  Google Scholar 

  27. Bristow MR, Thompson PD, Martin RP, Mason JW, Billingham ME, Harrison DC. Early anthracycline cardiotoxicity. Am J Med 1978;65:823–832.

    Article  PubMed  CAS  Google Scholar 

  28. Lewis AB, Crouse VL, Evans W, Takahashi M, Siegel SE. Recovery of left ventricular function following discontinuation of anthracycline chemotherapy in children. Pediatrics 1981;68:67–72.

    PubMed  CAS  Google Scholar 

  29. Moreb JS, Oblon DJ. Outcome of clinical congestive heart failure induced by anthracycline chemotherapy. Cancer (Phila) 1992;70:2637–2641.

    Article  PubMed  CAS  Google Scholar 

  30. Schwartz RG, McKenzie WB, Alexander J, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med 1987;82:1109–1118.

    Article  PubMed  CAS  Google Scholar 

  31. Bristow MR, Mason JW, Billingham ME, Daniels JR. Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. Am Heart J 1981;102:709–718.

    Article  PubMed  CAS  Google Scholar 

  32. McKillop JH, Bristow MR, Goris ML, Billingham ME, Bockemuehl K. Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity. Am Heart J 1983;106:1048–1056.

    Article  PubMed  CAS  Google Scholar 

  33. Lee BH, Goodenday LS, Muswick GJ, Yasnoff WA, Leighton RF, Skeel RT. Alterations in left ventricular diastolic function with doxorubicin therapy. J Am Coll Cardiol 1987;9:184–188.

    PubMed  CAS  Google Scholar 

  34. Hausdorf G, Morf G, Beron G, et al. Long term doxorubicin cardiotoxicity in childhood: non-invasive evaluation of the contractile state and diastolic filling. Br Heart J 1988;60:309–315.

    Article  PubMed  CAS  Google Scholar 

  35. Marchandise B, Schroeder E, Bosly A, et al. Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J 1989;118:92–98.

    Article  PubMed  CAS  Google Scholar 

  36. Stoddard MF, Seeger J, Liddell NE, Hadley TJ, Sullivan DM, Kupersmith J. Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans. J Am Coll Cardiol 1992;20:62–69.

    Article  PubMed  CAS  Google Scholar 

  37. Ganz WI, Sridhar KS, Forness TJ. Detection of early anthracycline cardiotoxicity by monitoring the peak filling rate. Am J Clin Oncol 1993;16:109–112.

    Article  PubMed  CAS  Google Scholar 

  38. Ewer MS, Ali MK, Gibbs HR, et al. Cardiac diastolic function in pediatric patients receiving doxorubicin. Acta Oncol 1994;33:645–649.

    PubMed  CAS  Google Scholar 

  39. Cottin Y, Touzery C, Coudert B, et al. Impairment of diastolic function during short-term anthracycline chemotherapy. Br Heart J 1995;73:61–64.

    Article  PubMed  CAS  Google Scholar 

  40. Schmitt K, Tulzer G, Merl M, et al. Early detection of doxorubicin and daunorubicin cardiotoxicity by echocardiography: diastolic versus systolic parameters. Eur J Pediatr 1995;154:201–204.

    Article  PubMed  CAS  Google Scholar 

  41. Mortensen SA, Olsen HS, Baandrup U. Chronic anthracycline cardiotoxicity: haemodynamic and histopathological manifestations suggesting a restrictive endomyocardial disease. Br Heart J 1986;55:274–282.

    Article  PubMed  CAS  Google Scholar 

  42. Billingham ME, Bristow MR. Evaluation of anthracycline cardiotoxicity: predictive ability and functional correlation of endomyocardial biopsy. Cancer Treat Symp 1984;3:71–76.

    Google Scholar 

  43. Pegelow CH, Popper RW, de Wit SA, King OY, Wilbur JR. Endomyocardial biopsy to monitor anthracycline therapy in children. J Clin Oncol 1984;2:443–446.

    PubMed  CAS  Google Scholar 

  44. Isner JM, Ferrans VJ, Cohen SR, et al. Clinical and morphologic cardiac findings after anthracycline chemotherapy. Analysis of 64 patients studied at necropsy. Am J Cardiol 1983;51:1167–1174.

    Article  PubMed  CAS  Google Scholar 

  45. Neri B, De Scalzi M, De Leonardis V, Gemelli MT, Ghezzi P, Pacini P. Preliminary study on behaviour of atrial natriuretic factor in anthracycline-related cardiac toxicity. Int J Clin Pharmacol Res 1991;11:75–81.

    PubMed  CAS  Google Scholar 

  46. Bauch M, Ester A, Kimura B, Victorica BE, Kedar A, Phillips MI. Atrial natriuretic peptide as a marker for doxorubicin-induced cardiotoxic effects. Cancer (Phila) 1992;69:1492–1497.

    Article  PubMed  CAS  Google Scholar 

  47. Tikanoja T, Riikonen P, Perkkio M, Helenius T. Serum N-terminal atrial natriuretic peptide (NT-ANP) in the cardiac follow-up in children with cancer. Med Pediatr Oncol 1998;31:73–78.

    Article  PubMed  CAS  Google Scholar 

  48. Suzuki T, Hayashi D, Yamazaki T, et al. Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J 1998;136:362–363.

    Article  PubMed  CAS  Google Scholar 

  49. Nousiainen T, Jantunen E, Vanninen E, Remes J, Vuolteenaho O, Hartikainen J. Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin’s lymphoma. Eur J Haematol 1999;62:135–141.

    Article  PubMed  CAS  Google Scholar 

  50. Yamashita J, Ogawa M, Nomura K. Plasma endothelin-1 and doxorubicin cardiotoxicity. N Engl J Med 1994;331:1528–1529.

    Article  PubMed  CAS  Google Scholar 

  51. Yamashita J, Ogawa M, Shirakusa T. Plasma endothelin-1 as a marker for doxorubicin cardiotoxicity. Int J Cancer 1995;62:542–547.

    Article  PubMed  CAS  Google Scholar 

  52. Lipshultz SE, Rifai N, Sallan SE, et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation 1997;96:2641–2648.

    PubMed  CAS  Google Scholar 

  53. Missov E, Calzolari C, Davy JM, Leclercq F, Rossi M, Pau B. Cardiac troponin I in patients with hematologic malignancies. Coron Artery Dis 1997;8:537–541.

    PubMed  CAS  Google Scholar 

  54. Ganzina F. 4′-epi-Doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data. Cancer Treat Rev 1983;10:1–22.

    Article  PubMed  CAS  Google Scholar 

  55. Jain KK, Casper ES, Geller NL, et al. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol 1985;3:818–826.

    PubMed  CAS  Google Scholar 

  56. Brambilla C, Rossi A, Bonfante V, et al. Phase II study of doxorubicin versus epirubicin in advanced breast cancer. Cancer Treat Rep 1986;70:261–266.

    PubMed  CAS  Google Scholar 

  57. Villani F, Galimberti M, Comazzi R, Crippa F. Evaluation of cardiac toxicity of idarubicin (4-demethoxydaunorubicin). Eur J Cancer Clin Oncol 1989;25:13–18.

    Article  PubMed  CAS  Google Scholar 

  58. Lopez M, Contegiacomo A, Vici P, et al. A prospective randomized trial of doxorubicin versus idarubicin in the treatment of advanced breast cancer. Cancer (Phila) 1989;64:2431–2436.

    Article  PubMed  CAS  Google Scholar 

  59. Speyer JL, Green MD, Kramer E, et al. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 1988;319:745–752.

    Article  PubMed  CAS  Google Scholar 

  60. Speyer JL, Green MD, Zeleniuch-Jacquotte A, et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 1992;10:117–127.

    PubMed  CAS  Google Scholar 

  61. Hochster H, Liebes L, Wadler S, et al. Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. J Natl Cancer Inst 1992;84:1725–1730.

    Article  PubMed  CAS  Google Scholar 

  62. Swain SM, Whaley FS, Gerber MC, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 1997;15:1318–1332.

    PubMed  CAS  Google Scholar 

  63. Hensley ML, Schuchter LM, Lindley C, et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 1999;17:3333–3355.

    PubMed  CAS  Google Scholar 

  64. Gill PS, Espina BM, Muggia F, et al. Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J Clin Oncol 1995;13:996–1003.

    PubMed  CAS  Google Scholar 

  65. Hempel G, Reinhardt D, Creutzig U, et al. Population pharmacokinetics of liposomal daunorubicin in children. Br J Clin Pharmacol 2003;56(4):370–377.

    Article  PubMed  CAS  Google Scholar 

  66. Liu FT, Kelsey SM, Newland AC, et al. Liposomal encapsulation diminishes daunorubicin-induced generation of reactive oxygen species, depletion of ATP, and necrotic cell death in human leukaemic cells. Br J Haematol 2002;117(2):333–342.

    Article  PubMed  CAS  Google Scholar 

  67. Sadava D, Coleman A, Kane SE. Liposomal daunorubicin overcomes drug resistance in human breast, ovarian, and lung carcinoma cells. J Liposome Res 2002;12(4):301–309.

    Article  PubMed  CAS  Google Scholar 

  68. Henderson BM, Dougherty WJ, James VC, Tilley LP, Noble JF. Safety assessment of a new anticancer compound, mitoxantrone, in beagle dogs: comparison with doxorubicin. I. Clinical observations. Cancer Treat Rep 1982;66:1139–1143.

    PubMed  CAS  Google Scholar 

  69. Sparano BM, Gordon G, Hall C, Iatropoulos MJ, Noble JF. Safety assessment of new anticancer compound, mitoxantrone, in beagle dogs: comparison with doxorubicin. II. Histologic and ultrastructural pathology. Cancer Treat Rep 1982;66:1145–1158

    PubMed  CAS  Google Scholar 

  70. Mather FJ, Simon RM, Clark GM, Von Hoff DD. Cardiotoxicity in patients treated with mitoxantrone: Southwest Oncology Group phase II studies. Cancer Treat Rep 1987;71:609–613.

    PubMed  CAS  Google Scholar 

  71. Posner LE, Dukart G, Goldberg J, Bernstein T, Cartwright K. Mitoxantrone: an overview of safety and toxicity. Invest New Drugs 1985;3:123–132.

    Article  PubMed  CAS  Google Scholar 

  72. Goldberg MA, Antin JH, Guinan EC, Rappeport JM. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood 1986;68:1114–1118.

    PubMed  CAS  Google Scholar 

  73. Dow E, Schulman H, Agura E. Cyclophosphamide cardiac injury mimicking acute myocardial infarction. Bone Marrow Transplant 1993;12:169–172.

    PubMed  CAS  Google Scholar 

  74. Gardner SF, Lazarus HM, Bednarczyk EM, et al. High-dose cyclophosphamide-induced myocardial damage during BMT: assessment by positron emission tomography. Bone Marrow Transplant 1993;12:139–144.

    PubMed  CAS  Google Scholar 

  75. Gottdiener JS, Appelbaum FR, Ferrans VJ, Deisseroth A, Ziegler J. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med 1981;141:758–763.

    Article  PubMed  CAS  Google Scholar 

  76. Steinherz LJ, Steinherz PG, Mangiacasale D, et al. Cardiac changes with cyclophosphamide. Med Pediatr Oncol 1981;9:417–422.

    Article  PubMed  CAS  Google Scholar 

  77. Goldberg MA, Antin JH, Guinan EC, Rappeport JM. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood 1986;68:1114–1118.

    PubMed  CAS  Google Scholar 

  78. Quezado ZM, Wilson WH, Cunnion RE, et al. High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med 1993;118:31–36.

    PubMed  CAS  Google Scholar 

  79. Buzdar AU, Legha SS, Tashima CK, et al. Adriamycin and mitomycin C: possible synergistic cardiotoxicity. Cancer Treat Rep 1978;62:1005–1008.

    PubMed  CAS  Google Scholar 

  80. Villani F, Comazzi R, Lacaita G, et al. Possible enhancement of the cardiotoxicity of doxorubicin when combined with mitomycin C. Med Oncol Tumor Pharmacother 1985;2:93–97.

    PubMed  CAS  Google Scholar 

  81. Verweij J, Funke-Kupper AJ, Teule GJ, Pinedo HM. A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C. Med Oncol Tumor Pharmacother 1988;5:159–163.

    PubMed  CAS  Google Scholar 

  82. Labianca R, Beretta G, Clerici M, Fraschini P, Luporini G. Cardiac toxicity of 5-fluorouracil: a study on 1083 patients. Tumori 1982;68:505–510.

    PubMed  CAS  Google Scholar 

  83. Patel B, Kloner RA, Ensley J, Al Sarraf M, Kish J, Wynne J. 5-Fluorouracil cardiotoxicity: left ventricular dysfunction and effect of coronary vasodilators. Am J Med Sci 1987;294:238–243.

    Article  PubMed  CAS  Google Scholar 

  84. Rezkalla S, Kloner RA, Ensley J, et al. Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study. J Clin Oncol 1989;7:509–514.

    PubMed  CAS  Google Scholar 

  85. De Forni M, Malet-Martino MC, Jaillais P, et al. Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol 1992;10:1795–1801.

    PubMed  Google Scholar 

  86. Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990;8:1263–1268.

    PubMed  CAS  Google Scholar 

  87. Rowinsky EK, McGuire WP, Guarnieri T, et al. Cardiac disturbances during the administration of taxol. J Clin Oncol 1991;9:1704–1712.

    PubMed  CAS  Google Scholar 

  88. Arbuck SG, Strauss H, Rowinsky E, et al. A reassessment of cardiac toxicity associated with taxol. J Natl Cancer Inst Monogr 1993;15:117–130.

    PubMed  Google Scholar 

  89. Perez EA. Doxorubicin and paclitaxel in the treatment of advanced breast cancer: efficacy and cardiac considerations. Cancer Invest 2001;19(2):155–164.

    Article  PubMed  CAS  Google Scholar 

  90. Gianni L, Dombernowsky P, Sledge G, et al. Cardiac function following combination therapy with paclitaxel and doxorubicin: an analysis of 657 women with advanced breast cancer. Ann Oncol 2001;12(8):1067–1073.

    Article  PubMed  CAS  Google Scholar 

  91. Ekholm E, Rantanen V, Syvanen K, Jalonen J, Antila K, Salminen E. Docetaxel does not impair cardiac autonomic function in breast cancer patients previously treated with anthracyclines. Anticancer Drugs 2002;13(4):425–429.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematology, Royal Manchester Children’s Hospital, Manchester, UK

    Maged I. Gharib MSc, MD, MRCP, MRCPath (Attending)

  2. Department of Haematology, University of Wales College of Medicine, Cardiff, Wales, UK

    Alan K. Burnett MD, FRCPath, FRCP(Glasgow), FRCP(Edinburgh), FRCP(London), FMSci (Professor)

Authors
  1. Maged I. Gharib MSc, MD, MRCP, MRCPath
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alan K. Burnett MD, FRCPath, FRCP(Glasgow), FRCP(Edinburgh), FRCP(London), FMSci
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Surgery Oncology, Department of Surgery, University of Michigan, Ann Arbor, MI, USA

    Alfred E. Chang MD (Hugh Cabot Professor of Surgery and Chief) (Hugh Cabot Professor of Surgery and Chief)

  2. Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA

    Daniel F. Hayes MD (Clinical Director) (Clinical Director)

  3. Department of Cardiothoracic Surgery, New York University School of Medicine and Comprehensive Cancer Center, New York, NY, USA

    Harvey I. Pass MD (Professor and Chief of Thoracic Surgery and Head) (Professor and Chief of Thoracic Surgery and Head)

  4. Thoracic Oncology, New York University School of Medicine and Comprehensive Cancer Center, New York, NY, USA

    Harvey I. Pass MD (Professor and Chief of Thoracic Surgery and Head) (Professor and Chief of Thoracic Surgery and Head)

  5. Department of Medicine, Harvard Medical School, USA

    Richard M. Stone MD (Associate Professor and Clinical Director) (Associate Professor and Clinical Director)

  6. Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, MA, USA

    Richard M. Stone MD (Associate Professor and Clinical Director) (Associate Professor and Clinical Director)

  7. Division of Cancer Prevention and Control Research, Jonsson Comprehensive Cancer Center at UCLA, USA

    Patricia A. Ganz MD (American Cancer Society Clinical Research Professor, Director and Professor) (American Cancer Society Clinical Research Professor, Director and Professor)

  8. Schools of Public Health and Medicine, University of California, Los Angeles, Los Angeles, CA, USA

    Patricia A. Ganz MD (American Cancer Society Clinical Research Professor, Director and Professor) (American Cancer Society Clinical Research Professor, Director and Professor)

  9. Department of Radiation Oncology, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, OH, USA

    Timothy J. Kinsella MD (Vincent K. Smith Professor and Chairman) (Vincent K. Smith Professor and Chairman)

  10. Department of Medicine, University of Wisconsin Comprehensive Cancer Center, Madison, WI, USA

    Joan H. Schiller MD (Melanie Heald Professor of Medical Oncology) (Melanie Heald Professor of Medical Oncology)

  11. Health Media Research Laboratory, Department of Health Behavior and Health Education, University of Michigan School of Public Health, USA

    Victor J. Strecher PhD, MPH (Professor and Director and Associate Director) (Professor and Director and Associate Director)

  12. Cancer Prevention and Control, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA

    Victor J. Strecher PhD, MPH (Professor and Director and Associate Director) (Professor and Director and Associate Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer Science+Business Media, Inc.

About this chapter

Cite this chapter

Gharib, M.I., Burnett, A.K. (2006). Cardiac Complications. In: Chang, A.E., et al. Oncology. Springer, New York, NY. https://doi.org/10.1007/0-387-31056-8_78

Download citation

  • DOI: https://doi.org/10.1007/0-387-31056-8_78

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-24291-0

  • Online ISBN: 978-0-387-31056-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation